Abstract
Androgen compounds are commonly used in the treatment of anemia in patients with end-stage renal disease. The two widely used androgen compounds, nandrolone decanoate (ND) and testosterone enanthate (TE), have been reported to improve anemia in this setting. We conducted a controlled crossover study to evaluate and compare the hematopoietic, anabolic, and endocrine effects of ND and TE in patients with end-stage renal disease. Four of ten patients receiving ND and two of nine patients receiving TE exhibited marked rises (> 1 g/dL) in their hemoglobin concentration, while others showed no significant response. Serum FSH and LH levels were elevated, and serum testosterone levels were reduced during the control periods. They all fell significantly ( p < 0.001) with the administration of ND. Serum FSH and LH levels similarly fell with TE administration, although serum testosterone levels rose (p < 0.001), the latter due to detection of TE on serum testosterone assay. Serum prolactin level was markedly elevated during the control period. It fell during the administration of ND and increased with the use of TE.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call